Preferred Label : Folfirinox-Bevacizumab Regimen;
NCIt synonyms : Folfirinox-Bevacizumab; Bevacizumab Plus Folfirinox; Folfirinox-Avastin; Folfirinox Plus Bevacizumab; Bevacizumab-Folfirinox; Folfirinox/Bevacizumab;
NCIt related terms : FOLFIRINOX and Bevacizumab; FOLFIRINOX and Bevacizumab-aybi; FOLFIRINOX and Bevacizumab-awwb (L-Leucovorin); FOLFIRINOX and Bevacizumab-equi; FOLFIRINOX and Bevacizumab-awwb; FOLFIRINOX and Bevacizumab-adcd; FOLFIRINOX and Bevacizumab-onbe (L-Leucovorin); FOLFIRINOX and Bevacizumab-bvzr; FOLFIRINOX and Bevacizumab-adcd (L-Leucovorin); FOLFIRINOX and Bevacizumab-aybi (L-Leucovorin); FOLFIRINOX and Bevacizumab-maly (L-Leucovorin); FOLFIRINOX and Bevacizumab-bvzr (L-Leucovorin); FOLFIRINOX and Bevacizumab-maly; FOLFIRINOX and Bevacizumab (L-Leucovorin); FOLFIRINOX and Bevacizumab-equi (L-Leucovorin); FOLFIRINOX and Bevacizumab-onbe;
NCIt definition : A regimen consisting of fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX),
and bevacizumab that may be used for the treatment of ampullary, appendiceal and small
bowel adenocarcinomas, and colorectal cancer.;
NCI Metathesaurus CUI : CL1905341;
Codes from synonyms : 39672; 127620; 127324; 127621; 127325; 127546; 127547; 14681; 127399; 127250; 127251; 127472; 127473; 127176; 127177; 127398;
Origin ID : C192056;
UMLS CUI : C5784864;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
